Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by LexOrbisManisha Singh and Pankaj Musyuni of LexOrbis discuss regulatory changes for medical device companies and the impact of COVID-19 on manufacturers -
Sponsored by Remfry & SagarBisman Kaur and Raashi Jain of Remfry & Sagar discuss how key judicial decisions have shaped trademark protection in India’s automotive industry
-
Sponsored by Liu, Shen & AssociatesJing Qu and Dongguo Liang of Liu Shen & Associates consider how to best define ‘persons skilled in the art’, while examining the development of AI technologies
-
Sponsored by Smart & BiggarDavid Schwartz of Smart & Biggar discusses the importance of diagnostic technologies and why the patent system must find an appropriate balance to encourage innovation in this area
-
Sponsored by LexOrbisManisha Singh and Simrat Kaur of LexOrbis analyse a Bombay High Court case involving the registration of ‘Covishield’
-
Sponsored by Basham Ringe y CorreaEduardo Kleinberg and Santiago Zubikarai of Basham Ringe y Correa explain how to prepare for when the Mexican Institute of Industrial Property decides damages in IP cases
